TIGIT/CD47 dual high expression predicts prognosis and is associated with immunotherapy response in lung squamous cell carcinoma.
Yue PengBin QiuFengwei TanJiachen XuFenglong BieHuayu HeLei LiuHe TianGuangyu BaiBolun ZhouYuan LiQilin HuaiZhenlin YangShugeng GaoPublished in: Thoracic cancer (2022)
We found that TIGIT and CD47 dual high expression was associated with poor prognosis in LUSC. We speculated that patients with dual high expression of CD47/TIGIT might be suitable for new target immunotherapy in the future.